Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program

Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024


USPTO grants additional method of use patent for ganaxolone in TSC

...

Related Keywords

United States ,China ,Australia ,Canada ,Israel ,Alex Aimetti ,Joseph Hulihan ,Nasdaq ,Marinus Pharmaceuticals ,Trademark Office ,Marinus Pharmaceuticals Inc ,Exchange Commission ,Chief Scientific Officer ,Chief Medical Officer ,Marinu Phase ,New Drug Application ,Drug Administration ,United States Patent ,Western Europe ,Private Securities Litigation Reform Act ,